This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Discussion “Comparsion of the Bieoquvalence of Generic Versus Branded Clozapine”


Published: April 1, 2001

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Dr. Meyer: How does the evidence presented today speak to the issues of bioavailability, bioequivalence, and interchangeability for clozapine? Are we convinced that there is no problem whatsoever with the 100-mg tablet of the generic product?

Dr. Lam: I think the reverse is true.

Dr. Glazer: The signal that is emerging from the available studies gives us reason for concern.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: